Dear Managed Care Colleagues,

Welcome to our spring 2023 issue of the Magellan Rx Report! Since the release of our last edition in the fall, Magellan Rx has joined forces with Prime Therapeutics to usher in the next chapter of our company's evolution. This transformational opportunity enables us to build upon our thought leadership expertise in managed care pharmacy to create a brighter future for our industry and deliver even more value to those we serve. As a result, we will continue to keep our readers informed on the latest managed care trends and treatment updates, shining a bright light on insights and opportunities for the future.

In this edition of the report, we've captured this year's momentum with the FDA approval of five novel drugs and an expansive pipeline full of promising new agents across chronic conditions for the remainder of 2023. Our cover story (page 26) focuses on innovative CAR-T therapy. We review the landscape of CAR-T with a comprehensive review of the currently approved and available CAR-T therapies, as well as highlighting recent CAR-T approvals. The article also outlines the pipeline in this category as well as potential payer management strategies.

Another article (page 6) focuses on the imminent impact of adalimumab biosimilars entering the market. As the first adalimumab biosimilar launched in January, with more anticipated launches throughout 2023, this space will see a major shift in management and reimbursement for payers and manufacturers alike.

In our hemophilia article (page 10), we highlight the recent approvals of gene therapies in this category and the pipeline of gene therapies on the horizon for hemophilia. We also discuss how these innovative treatment options will impact payers, making hemophilia a high-priority management category.

Other topics in this issue include a dive into Alzheimer’s disease and recent advances (page 15), a brief rare disease update and pipeline (page 22), and an oncology update on current developments in breast cancer treatment (page 32). As always, the issue is rounded out with our pipeline update (page 38) and managed care newsstand (page 4).

To learn more about Magellan Rx Management and our support for payer initiatives of the future, please feel free to contact us at MagellanRxReport@magellanhealth.com. As always, we value any feedback you may have. I hope you enjoy the report!

Sincerely,

Mostafa Kamal Chief Executive Officer Magellan Rx Management

SUBSCRIBE TODAY!

Stay on top of managed care trends and become a Magellan Rx Report subscriber. Email us at MagellanRxReport@magellanhealth.com to subscribe today. Magellan Rx Report provides pharmacy and medical management solutions for managed care executives and clinicians. We hope you enjoy the issue; thank you for reading.